key: cord-0983737-ef03tk99
authors: Qiao, Qi; Liu, Xiong; Yang, Ting; Cui, Kexin; Kong, Li; Yang, Conglian; Zhang, Zhiping
title: Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design
date: 2021-05-07
journal: Acta Pharm Sin B
DOI: 10.1016/j.apsb.2021.04.023
sha: c56b20b997b1b64d8ce5c777c7a3171b87872c77
doc_id: 983737
cord_uid: ef03tk99

Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air-blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.

Animal model is of great importance for investigating etiology and pathological mechanisms of ARDS and exploiting available treatments. It can be established by activating lung inflammation directly or indirectly to mimic human lung environment.

Intratracheal/intranasal instillation or inhalation of lipopolysaccharide (LPS) is regarded as the practical method to establish an ARDS model in mice or rats 46 Plenty of drugs have demonstrated certain degree of therapeutic effects in animal models. Unfortunately, among thousands of drugs tested in clinical trials, none has succeeded for ARDS therapy. Therefore, effective pharmacologic treatments and proper animal models remain challenging. It is conducive to provide precise management on lung injury through more comprehensive investigation into the underlying pathogenesis of ARDS, more reliable models to mimic the complicated pathological process, and deeper exploitation on pharmaceutic means. 8 enzymes, and peptides [70] [71] [72] [82] [83] [84] [85] . Inhibitors or antagonists of key inflammatory pathways that act on cells or mediators have been extensively inspected for ARDS treatment, such as phosphodiesterase 4 (PDE4) inhibitor 86,87 , neutrophil elastase inhibitor 16 , IKK-2 inhibitor 27 , and chemokines receptor 2 antagonist 88 . Some of them encounter unsatisfied characteristics such as inadequate solubility, instability, and short half-life in vivo, severely impeding the therapeutic efficacy and leading to unsatisfactory clinical outcomes 83 . For instance, the Src tyrosine kinase inhibitor (PP2)

can be applied to treat acute lung inflammation, while its low solubility restricts its use. To minimize the component of solvent dimethyl sulfoxide (a toxic organic solvent to increase the solubility for injection), a nanoformulation was developed to improve the solubility, employing self-assembled peptides (EAK16-II) together with amino acids 83 . Therefore, the biocompatibility was significantly enhanced, displaying reduced infiltration of inflammatory cells and secretion of TNF-α in pretreatment for ARDS. Exogenous NE inhibitor, sivelestat, has shown benefits in ARDS mouse model, but it is still controversial in clinical trials 89, 90 . It may be due to the inefficiency of drug administration, as sivelestat is a small molecular selective inhibitor with poor pharmacokinetics and requires multiple doses 91 . To improve the efficacy, lipid-based nanocarriers were fabricated for sivelestat delivery, which executed effective inhibition on neutrophils and provided better therapeutic effects over free sivelestat 70 . Endogenous NE inhibitors, such as secretory leukocyte protease inhibitor, failed to tackle NE activity 92 . In another study, recombinant secretory leukocyte protease inhibitor was encapsulated in liposomes with further micronization into liposomal dry powders 92 . The liposomal dry powders improved structural integrity and the size stability during storage, maintained the activity of anti-NE and protected it from degradation by cathepsin. Enzymes like DNase-I and catalase are used for suppressing inflammation, but the instability can discount their effect.

Various nanocarriers have been developed to achieve effective delivery by keeping the enzyme activity and extending action time 71, 72, 84 .

Importantly, nanocarriers can greatly alter the drug biodistribution in pre-clinical studies. Accumulated evidences indicated that nanoparticles may undergo distinct biodistribution behavior between healthy and ARDS animals, regardless of targeting modification 56,64,78,93,94 . It was found that cationic liposomes demonstrated up to 1.54-fold accumulation in inflamed lungs compared to healthy ones 93 . Similarly, β-cyclodextrin nanoparticles reached 1.3-fold accumulation in inflamed lungs 78 .

Besides, it is documented that cationic liposomes consisting of 50% (mol/mol) 1-diolefin-3-trimethylaminopropane (DOTAP) generated up to double accumulation in the inflamed lung tissues compared with healthy lungs in rats after intravenous (i.v.) injection 93 . The apparent difference in biodistribution of nanocarriers between normal and ARDS animals reflects the leakage of vascular system during the pathophysiological process, which may promote the passive targeting of nanocarriers, thus improving therapeutic efficiency. Furthermore, active targeting modification on nanocarriers can be realized by taking advantage of specific and highly expressed molecules in the inflammatory microenvironment, to accomplish more precise distribution 57 .

For the fact that ARDS patients are often vulnerable to multiple organ dysfunction, non-target side effects of drugs may aggravate the progress of the disease 95 . Therefore, there is tremendous clinical significance to realize targeted delivery for increasing efficiency while reducing toxicity.

Both passive and active targeting strategies can motivate lung distribution and cellular uptake, ultimately promoting the therapeutic effects while avoiding adverse reactions. For instance, glucocorticoids are regarded as potent anti-inflammatory drugs, while clinicians have to weigh the benefits and detriments. In this regard, multiple nanocarriers have been utilized to improve the therapeutic efficiency and decline side effects, including polymeric nanoparticles 96 , liposomes 28,58,61 , nanostructured lipid carriers 56 , polymer micelles 55 , nanogels 59 , bovine serum albumin (BSA) nanoparticles 62 , and monocyte membrane-derived vesicles 60 . For another example, PDE4 inhibitors can be detrimental due to unintended brain distribution.

Encapsulation into lipid-based nanocarriers such as nanovesicles and nanoemulsions can reduce their biodistribution in the brain considerably 86, 87 . Statins possess anti-inflammation and antioxidant properties, while the potential hepatotoxicity discourages their clinical application 97 . Thereby, nanostructured lipid carriers with intercellular adhesion molecule-1 (ICAM-1) antibody modification were adapted for the targeting delivery to provide effective therapy with negligible side effects 65,66 .

J o u r n a l P r e -p r o o f conditions may alter the fate of nanoparticles, therapeutic scheme (intervention time and administration route), and physicochemical properties (size, shape, surface charge, hydrophilicity, and modification) can have a specific influence on the pharmacokinetics and cellular uptake behavior, which ultimately determine the therapeutic effect 79, 104 .

In pre-clinical studies, therapeutic schedule can be diverse, depending on drug property, acting site, and targeting mechanism. Both systemic and pulmonary administration routes are adopted in ARDS treatment. The administration time and routes may impact the delivery and therapeutic efficiency to some extent 79 . As an example, the therapeutic outcome of polydopamine (PDA) nanoparticles was evaluated among different intervention timepoint post-LPS challenge via different administration pathway (i.v. or intranasally administration) 79 . It was reported that the earlier PDA nanoparticles were administrated, the better therapeutic outcome could be achieved in both injection ways. Given the rapid development of this disease, the time window for practical application of nanomedicine may be very narrow. In clinical, it was evidenced that the first week after ARDS onset represented a critical period for potential therapeutics 105 . It was also reported that the intranasal administration route achieved a better therapeutic outcome as indicated by a ~1.3-fold decrease in both total protein content and neutrophil counts in bronchoalveolar lavage fluid (BALF) 79 .

The pulmonary administration route provides a non-invasive method for drug delivery to the lungs 19 . Various nanocarriers have been evaluated for pulmonary delivery, as listed in Table S2 29-31,52-54,61, [73] [74] [75] 79 ,83,96,99,100, [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] . Importantly, gene therapies usually adopt pulmonary administration to take immediate effect for ARDS treatment 29-31, [73] [74] [75] 96, 99, 100 . In addition, some antioxidant and anti-inflammatory molecules delivered by nanocarriers also conducted pulmonary administration 52,53,61,83,112 . Nanoparticles administrated through pulmonary route need to surmount multiple structured layers or biological barriers, including mucus, epithelium, endothelium, interstitial space, pulmonary surfactant, and innate immune system 117 . Physicochemical properties, including particle size, surface charge, and hydrophilicity, could impact the clearance and translocation of nanoparticles in lung tissues 118 . As physicochemical properties that affect the fate of nanoparticles after J o u r n a l P r e -p r o o f lung deposition have been excellently reviewed 118 , we mainly focus on factors influencing non-pulmonary drug delivery for ARDS treatment and provide general discussions in the following parts.

Particle size has a significant influence on the fate of nanoparticles, which can alter physical properties of nanoparticles, resulting in the differences in drug release, cellular uptake, and pharmacokinetic behavior in vivo 119 . For example, larger-sized nanoemulsions showed lower lipophilicity than smaller-sized nanoemulsions 67 . Thus, the drug release rate was much slower than smaller-sized formulations.

In general, enhanced lung accumulation and uptake by phagocytic cells is correlated to the increase of particle size 67,120 . 

The surface characteristic is also vital for lung accumulation and cellular uptake 119 .

Both negatively charged and positively charged nanocarriers are investigated in ARDS treatment. It seems that positively charged nanocarriers can attain better accumulation and cellular uptake. And it also enhanced cellular uptake of activated endothelial cells in vitro and J o u r n a l P r e -p r o o f exhibited a more robust distribution of 1.25-fold than cationic ones in inflamed lungs in vivo.

Although the morphology of nanoparticles has proved to be associated with cellular internalization, shape effects have not yet been completely elucidated in ARDS treatment 124 . The extensively studied particles in vivo are spherical. The trend of cell uptake may vary from cell to cell 125, 126 . ICAM or platelet-endothelial cell adhesion molecule (PECAM-1) antibody-coated spheres were internalized more efficiently by endothelial cells than polymorphous conjugates, which could further benefit the endothelial delivery of superoxide dismutase and exert their protection against ROS 125 .

For macrophages, particle shape is central for the phagocytosis process, and elongated particles are known to undergo reduced uptake 126 . In contrast, both in vitro and in vivo studies have exhibited opposite trends that polymeric rod particles were preferentially phagocytosed by neutrophils compared with sphere-shaped particles, which could offer an opportunity for selective targeting in acute inflammations featured with excessive neutrophils 126 . Further understanding of how physical parameters of particles influence their specific interaction within various immune cells will inspire us with more specific and feasible designs for drug delivery in ARDS treatment.

Hydrophobic nanoparticles have long been regarded to boost immune activation, while hydrophilic nanoparticles can modulate the immune system in the opposite direction 106, 127 . The underlying mechanism may be ascribed to that hydrophobic portions are essential parts of endogenous and exogenous immune stimulators, which may initiate innate immune responses 106 . The role of hydrophilic polymer nanoparticles in immune regulation was studied by exploring poly(ethylene glycol) (PEG), poly(carboxybetaine) (PCB), and poly(sulfobetaine) hydrogels 106 . In vitro and in vivo findings revealed that hydrophilic nanogels could weaken the immune response promoted by LPS and rebuild the balance of the immune system. Among them, PCB nanogels possessed the highest degree of hydrophilicity and showed the most significant relief of immune response, as indicated by a reduced number of infiltrating cells as well as levels of TNF-α and IL-6, and further observation of J o u r n a l P r e -p r o o f decreased phagocyte activation. Thus, the immune-regulation ability of nanoparticles may be associated with their hydrophilicity, which helps to resist non-specific binding.

Since surface hydrophilicity is closely related to the immunomodulatory properties, modifying these factors can reduce possible pro-inflammatory properties of delivery systems and make them suitable drug carriers 128 .

To achieve better accumulation and retention in the lungs, surface modification on nanoparticles has been widespread 74, [129] [130] [131] [132] 74, 130 . For non-pulmonary delivery, PEGylation has also be hired for extending the blood circulation 71, 72 . Importantly, small molecules, antibodies, peptides, and membrane proteins can be harnessed as targeting ligands to facilitate the delivery to desired areas, thus improving the therapeutic index. Surface modification can achieve the targeting for specific cells, including vascular endothelium cells and immune cells, which will be introduced in detail in the following parts.

The fate and impact of nanoparticle delivery in ARDS situations have not been investigated or recorded in detail. Deeper understanding of the influencing factors in the nanocarriers-based delivery system is of great importance to improve lung biodistribution and evade the possible but unwanted clearance or side effects in vivo, ensuring subsequent good therapeutic effect. More detailed surveys on the progression of barrier disruptions, corresponding vascular permeability, and other characteristics of inflammatory environment may provide directions on the property optimization of nanocarriers and delivery strategies for ARDS therapies 14 .

Targeted delivery strategies have been generally applied in ARDS treatment, especially for systemic drug delivery, which remains a common choice for nanodrug J o u r n a l P r e -p r o o f therapy. It was observed that leaky vasculature could form due to the destruction of pulmonary interstitial and alveolar structure 39, 133 Fig. 3 .

The lung is regarded as the most important organ for gas change, where the pulmonary vasculature occupies 25%-30% of whole endothelial surface in vascular networks 134 .

Nanocarriers can passively accumulate in lung injury sites after systemic administration, which may be attributed to the increased permeability of pathological vasculature in inflammatory areas. The applications of nanomedicine for passive targeting delivery are summarized in Table 1 

Compared with passive targeting, active targeting strategy may provide more feasibility on engineering nanoparticles to target interesting cells using specific ligands, aiming for the optimal and accurate drug delivery 138 . In some cases, the decoration of functional molecules can not only endow the nanocarriers with targeting

properties, but also participate in the regulation of inflammatory 145 

The pulmonary endothelium performs as a critical regulatory interface between blood and alveoli, playing a pivotal role in the occurrence and further expansion of ARDS inflammation 33 . Endothelium damage has been confirmed in COVID-19 hospitalized patients as one of the essential features related to severe illness and death 158, 159 . It is proposed that strategies to reduce endothelium damage may improve the prognosis of COVID-19. Endothelium-targeted drug therapies have been extensively employed in treating common acute pathological conditions 138, 160 . Activated endothelium has offered targeting sites in the inflamed tissue for therapeutic nanoparticles 138 . The highly expressed surface markers on inflammatory endothelial cells prompt researchers to explore targeting modification 160 .

Multiple tactics have been engaged in endothelial targeting through ligand conjugation on the surface of nanocarriers 160, 161 . Antibody and their derivatives, such as single chain variable fragments (scFv), peptides, and receptor ligands, are commonly used targeting ligands 160, 161 . The targeting efficiency differs according to the type and affinity of ligands, as well as the size, shape, and surface charge of the whole system 125, 162 . More advanced means inspiring by nature have been investigated which will be introduced in a separate part (seen in Section 6.2).

As the most abundant and essential white blood cells in the innate immune system, neutrophils play a vital role in manipulating acute inflammation 42 . When ARDS occurs, neutrophils are firstly recruited to the lungs to resist foreign pathogenic microorganisms 14, 168 . However, the accumulation of excessive neutrophils in the pulmonary microcirculation, interstitium, and alveolar spaces, can trigger uncontrolled inflammatory response, further leading to the damage of pulmonary microvascular and endothelial, and tissue injury 154 . Treatment strategy based on neutrophils has attracted much attention. It is reported that reducing the number of neutrophils alone may lead to a neutropenia-related infection 154, 169 . Therefore, it is necessary to design more intelligent drug delivery system to effectively reverse the overactivation of neutrophils while keeping the normal function of neutrophils.

Therapeutic strategies for targeting neutrophils involve disturbing neutrophils recruitment and migration, increasing internalization by activated neutrophils, and inhibiting neutrophil-derived inflammatory mediators.

It is well-documented that neutrophils can leave the circulation and migrate to inflamed sites through complicated sequence of recruitment processes in response to environmental stimuli 169 . In this regard, various intercellular adhesions and migration gradient get involved in the interactions between neutrophils and vascular systems, which may finally cause immoderate neutrophils recruitment and migration 170 . Thus, nanoparticles that can segregate circulating neutrophils, or interrupt the interaction with recruitment mediators, may reduce the migration and infiltration of neutrophils towards lung tissues.

Polystyrene carboxylate-modified particles with size of 0.5 or 2 μm could interfere with neutrophils adhesion and migration within vasculature 171 . As observed J o u r n a l P r e -p r o o f in ARDS model, these particles displayed the capability of rapidly binding and sequestering with circulating blood neutrophils after i.v. injection, and decreased airway neutrophil accumulation as much as ~95% versus particle-free BALB/c mice.

Such findings may inspire researchers to search for novel designs toward trapping inflammatory cells such as neutrophils, monocytes/macrophages, and platelets, which could induce inflammation and injury during ARDS.

Inhibiting the interactions of neutrophils with endothelium is another approach to Recently, another research found that liposomes composed of inverse phosphocholine lipids could rapidly enrich complement fragment iC3b and be hijacked by activated neutrophils via the interaction with cell-bound complement receptor CR3 173 . Then, the neutrophils containing liposomes could migrate across the alveolar-capillary barrier, accumulate in the inflamed lungs in a few hours, and release drugs to achieve remarkable therapeutic efficacy.

Neutrophils can undergo a typical process, namely NETosis, to generate and release reticular NETs (consisting of DNA and proteins), thus performing their anti-infective activity 175 . However, it was conveyed that overproduced NETs may also cause tissue damage and be associated with the onset and activation of ARDS 176 . Thus, targeting NET-mediated pathology by blocking neutrophil-derived mediators provides new insight for ARDS.

NE is an essential inflammatory mediator formed by neutrophils, which can promote NETs formation. The inhibition of NE can suppress NETs induced tissue injury 70 . As an exogenous NE inhibitor, sivelestat has displayed outstanding performance in ARDS medication. Free sivelestat did not show efficacy in mouse suffered endotoxic shock, while sivelestat-loaded vesicles could promote drug uptake by neutrophils and remarkably improve the effectiveness in disturbing NET formation and reducing lung injury 70 .

Besides, DNase-I, a kind of DNA degrading enzyme, is found to combat inflammation by inhibiting NETosis in experimental animals 71, 72 . However, its short half-life has restricted the activity. PDA nanoparticles with this enzyme immobilized on the surface were developed to improve the stability, extend lung accumulation, and achieve long-acting in circulation (Fig. 5A ) 71 . These nanoparticles maintained their J o u r n a l P r e -p r o o f 26 activity and resolved sepsis-associated NETosis, as evidenced by the decline of neutrophil numbers and inflammatory markers in lung tissues compared with free DNase-I ( Fig. 5B-D) . Likewise, another research employed PDA to settle DNase-I on the surface of melanin-like nanospheres 72 . This system also reduced the inflammatory response and alleviated lung damage in the septic ARDS model.

During the ARDS inflammatory activation process, the polarization of AM exists a dynamic conversion between pro-inflammatory M1 and anti-inflammatory M2 

Physicochemical targeting delivery has also been broadly used in ARDS treatment 

In ARDS, many inflammatory cells can release proteases 3 . In this regard, various enzyme-responsive materials have been utilized to improve drug delivery efficiency 136 .

For example, MPO is abnormally produced in neutrophils under inflammatory conditions. Based on this theory, biodegradable nanovesicles were fabricated by self-assembly of CD-derived materials with luminescence (Lu-bCD) for effective tracking, imaging, and quantification of activated neutrophils (Fig. 6A ) 136 . This MPO-responsive nanoprobe showed specific and sustainable luminescence signals after triggering even in deep tissues of acute lung injury, implying a promising strategy for precise delivery of therapeutic drugs (Fig. 6B-E) .

NE-responsive materials were also exploited 156 . Taking advantage of the excessive neutrophil elastase released from the pulmonary inflammatory microenvironment, NE-sensitive peptides could be employed to achieve specific protease-triggered rapid degradation of microgels, leading to the release of encapsulated Nexinhib20 (a potent 

Except for the elevated ROS and enzyme levels, lower pH than normal tissue was also reported 27, 190, 191 

Apart from the universal design of nanoparticles for drug delivery, other novel strategies have been emerging, including cell hitchhiking technology, bioinspired engineering, pulmonary surfactant-based strategy, and particle allosteric strategy, and nanovaccines.

Multiple circulatory cells including RBCs, neutrophils, monocytes/macrophages, and platelets, can migrate to lung tissues during the physiological or pathological process, such as blood circulation and inflammation homing 193 . Therefore, many innovative drug delivery systems have been widely developed by utilizing these features 193 , aiming to solve the limit of nanocarriers that most drugs will be eliminated in circulation and may not be able to reach the affected area directly 194 .

Cell hitchhiking technology has been engaged in drug delivery for ARDS therapy [195] [196] [197] Through the imaging, it was found that human amniotic fluid stem cells performed much better than mouse bone marrow mesenchymal stem cells in terms of lung tissue repair, highlighting a promising technology for imaging-guided therapy in ARDS 197 .

Cell membrane/EV-based delivery strategies hold great potential for effective countermeasures against overwhelming inflammations with multiple benefits in improving biocompatibility, exerting targeting properties, neutralizing endotoxin/virus or inflammatory derivatives, and modulating immune systems 69,203,204 . 221 . We note that superb reviews have summarized the applications of MSC-EVs for ARDS therapy. Thus, it will only be discussed briefly as follow 221, 222 .

such as bone marrow, adipose tissues, and umbilical cord blood, and their therapeutic effects have been explored in pre-clinical and clinical researches for ARDS [223] [224] [225] [226] .

Many studies have revealed that MSC-EVs could transfer various substances such as miRNA, mRNA, proteins, and mitochondrion to realize the amelioration for ARDS 217 .

also communicate with various pulmonary cells, including lung epithelial or endothelial cells, to adjust the lung permeability and repair damaged tissues 221 J o u r n a l P r e -p r o o f

progression, it was reported that platelet-derived extracellular vesicles (PEVs) did not aggravate inflammation after reaching the inflamed regions 63 . Taking advantage of the intrinsic affinity of platelets to inflammation sites, the engineered PEVs improved the lung delivery of TPCA-1, exerted significant inhibition on the infiltration of pulmonary inflammatory cells, and blocked cytokine storm (Fig. 9A ) 63 . The PEVs demonstrated 3.6-fold of enhanced lung accumulation in ARDS mice compared to normal mice, possibly due to their selective binding to activated/inflamed sites via receptor patterns ( Fig. 9B and C) , such as CD40L, glycoproteins, and P-selectin 63,233 . which can reduce alveolar and interstitial neutrophil infiltration, reduce MPO activity, restore the integrity of epithelial barrier system and reverse pulmonary edema 111 .

When delivering drugs to deep lungs, it is hard to hurdle the biological barrier that 

As surfactant proteins are critical ingredients of lung surfactant, thus they can be utilized for alveolar epithelial targeting modification 28,58,235 . SP-A is highly and specifically expressed in AEC II. Thereby, SP-A antibody functionalized immunoliposome can be employed for lung-specific targeting 58 . Consequently, the concentration and residence time of dexamethasone in the lung tissue remarkably increased. However, the complete antibody may lead to rapid clearance from the circulation. Thus, anti-rat SP-A nanobody (rSPANb) with low molecular weight and low immunogenicity was further studied. Methylprednisolone was loaded into nano-sterically stabilized unilamellar liposomes with rSPANb functionalized 28 .

Compared with the SP-A polyclonal antibody, these rSPANb conjugated nanoparticles exerted high affinity and stable structure, showing more senior safety and more specific lung targeting properties. For another example, lipoplexes with SP-C antibody conjugated could be a popular platform for microRNA delivery and treatment for pulmonary disease, attributing to targeting lung AEC II with specificity as much as 70% 109 . In addition, with a pulmonary surfactant layer coating, the reconstructed siRNA-loaded nanogels improved the stability of particles and enhanced the J o u r n a l P r e -p r o o f intracellular siRNA delivery observably 75 . With fusogenic properties, SP-B was identified to be the determining factor that enhanced cytosolic siRNA delivery.

Besides, these hybrid nanogels could be efficiently internalized by resident alveolar macrophages and demonstrated low toxicity.

Instead of active ingredients such as lipids, proteins, and peptides, synthetic polymers can be exploited as promising candidates for pulmonary surfactants 108 .

Poly(styrene-b-ethylene glycol) (PS-PEG) polymer nanomicelles displayed a strong affinity to the air-water interface, thus producing extraordinarily low surface tension under high compression 108 .

For the pulmonary delivery of nanoparticles, an aerodynamic particle size of 1-5 μm is requested for inhalation to deliver the active ingredient to lower respiratory systems 242 , whereas particles with this geometric diameter are readily phagocytosed by macrophages and rapidly cleared. Most nanoparticles are out of this size range and might result in aggregation into larger particles or get exhaled 243 . However, smaller particles may achieve more effective intracellular delivery 244 . Those paradoxical constraints on particle size may obstruct the effective therapy for lung disease, and particle size allosteric strategy is promising to satisfy the specific needs for pulmonary delivery 156 . For instance, neutrophil elastase-sensitive nanoparticles-in-microgels (N-in-M) were designed (Fig. 10A ) 156 . With a size under 200 nm, Nexinhib20-loaded PLGA nanoparticles could facilitate the intracellular delivery. PLGA nanoparticles were embedded into degradable microgels that were cross-linked by NE-sensitive peptides. With a diameter of 3.9 μm, the microgels achieved an appropriate aerodynamic size for deep lung deposition. The microgels were degraded triggered by neutrophil elastase, after which PLGA nanoparticles accomplished the delivery of Nexinhib20 to the airway and internalized by polymorphonuclear neutrophils, leading to substantial reduction of systemic and lung inflammation signaling (Fig. 10B-D) .

Currently, many repurposed and antiviral drugs that aim to suppress ARDS symptoms have been approved to manage COVID-19 245 Thus, nanovaccines can be of great potential in the therapy for virus-induced ARDS.

Based on the comprehension of pathogenesis, nanoparticles for early diagnosis, drug delivery, and gene therapy of ARDS have achieved considerable progress in the past decade. The major applications based on nanomaterials for ARDS can be summarized into four aspects: (i) employing as a carrier for small molecules, peptides, nucleic acids, etc., to improve drug solubility, stability, and bioavailability, or realize co-delivery; (ii) utilizing inherent antioxidant and immunomodulatory effects of materials; (iii) exploiting distinct nanoparticles which are prone to be internalized by targeted cells to provoke effective cellular delivery; (iv) overcoming multiple pulmonary barriers to enhance drug accumulation at inflammatory sites through passive or active targeting effect, or developing bioactive or responsive nanomaterials to obtain site-specific or stimuli-responsive drug release.

To date, precise nano-therapy for ARDS has primarily concentrated on the endothelium-targeted delivery, inhibiting pathological-related inflammatory cells by Ensuring the safety of nanocarriers is essential for clinical translation. Although some are non-inflammatory with certain safety or even display internal anti-inflammatory or antioxidant activity, it is still important to clarify their potential toxicity, especially for pulmonary delivery. A comprehensive understanding of the interaction of nanoparticles with immune systems and lung cells is conducive to accomplish safer and more efficient nano-therapy for ARDS.

In summary, nanomedicine-based drug delivery systems for the prevention, diagnosis, and treatment of ARDS have excellent clinical application prospects, which are expected to provide a new paradigm for ARDS drug therapy. More reliable models and more in-depth understanding of underlying mechanisms and interactions will encourage more rational designs of novel drug delivery systems with precise targeting for ARDS therapy, which could fill the existing gap in clinical translation.

Considering numerous links between ARDS and COVID-19, it is promising that ARDS relevant investigations will contribute to promoting potential therapies for delivery. Physicochemical properties can be manipulated for optimal drug delivery, including particle size, charge, shape, and hydrophilicity. Through engineering approaches such as modification or conjugation with specific molecules, peptides antibody, or membrane proteins on the surface, nanocarriers can accomplish passive, active, and physicochemical targeting. The therapeutic effect of drug delivery systems was mainly conducted in animals with few studies on human lung sections.

Therapeutic regimens including administration time and route can also influence drug efficiency. 

Acute respiratory distress syndrome: advances in diagnosis and treatment

Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 Countries

Acute respiratory distress syndrome. N COVID-19

Acute respiratory distress syndrome: the Berlin definition

Acute respiratory distress syndrome

Lung protection in acute respiratory distress syndrome: what should we target?

Efficacy of early sivelestat administration on acute lung injury and acute respiratory distress syndrome

Early D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice

The endothelium in acute lung injury/acute respiratory distress syndrome

Into the eye of the cytokine storm

Cytokine release syndrome in severe COVID-19

Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome

Acute lung injury: A clinical and molecular review

Lung under attack by COVID-19-induced cytokine storm: Pathogenic mechanisms and therapeutic implications

The acute respiratory distress syndrome: Pathogenesis and treatment

Lung microvascular niche, repair, and engineering

Regulation and repair of the alveolar-capillary barrier in acute lung injury

Contribution of neutrophils to acute lung injury. Mol neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy

Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock

Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm

Bioinspired DNase-I-coated melanin-like nanospheres for modulation of infectionassociated NETosis dysregulation

Anti-inflammatory effect of anti-TNF-α siRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model

Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury

Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy

Principles of nanoparticle design for overcoming

Analysis of nanoparticle delivery to tumours

Prior lung inflammation impacts on body distribution of gold nanoparticles

The impact of pulmonary diseases on the fate of inhaled medicines-a review

Pharmacokinetics and biodistribution of nanoparticles

Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies

Mitigation of inflammatory immune responses with hydrophilic nanoparticles

Dimethyl silicone dry nanoemulsion inhalations: Formulation study and anti-acute lung injury effect

Polymer lung surfactants

CRISPR-Cas gene editing

Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines

Strategies in the design of nanoparticles for therapeutic applications

Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates

Neutrophils preferentially phagocytose elongated particles-an opportunity for selective targeting in acute inflammatory diseases

Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses

Immunological properties of engineered nanomaterials

Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses

PEGylation of cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and enhances cellular uptake in the lung

Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials

PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages

Mechanisms responsible for increased vascular permeability in airway and systemic inflammation

Design and development of novel mitochondrial targeted nanocarriers, DQAsomes for curcumin inhalation

Endothelial damage in acute respiratory distress syndrome

Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study

Targeted endothelial nanomedicine for common acute pathological conditions

Targeting therapeutics to endothelium: Are we there yet

Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactor

Endothelial pathomechanisms in acute lung injury

PECAM-targeted delivery of SOD inhibits endothelial inflammatory response

Nanostructured lipid carriers-based drug delivery for treating various lung diseases: a state-of-the-art review

Vascular targeting of radiolabeled liposomes with bio-orthogonally conjugated ligands: Single chain fragments provide higher specificity than antibodies

Non-invasive detection of lung inflammation by near-infrared fluorescence imaging using bimodal liposomes

Neutrophil-based drug delivery systems

Neutrophils as emerging therapeutic targets

Neutrophil recruitment and function in health and inflammation

Neutrophil-particle interactions in blood circulation drive particle clearance and alter neutrophil responses in acute inflammation

Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke

Voluntary-opsonization-enabled precision nanomedicines for inflammation treatment

Regulation of the expression of Fcg receptor on circulating neutrophils and monocytes in Kawasaki disease

Extracellular DNA traps in inflammation, injury and healing

Neutrophil extracellular traps in immunity and disease

Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases

Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs

Amino acid-dependent attenuation of Toll-like receptor signaling by peptide-gold nanoparticle hybrids

Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice

Triphenylphosphonium decorated liposomes and dendritic polymers: Prospective second generation drug delivery systems for targeting mitochondria

Using nano-selenium to combat Coronavirus Disease 2019 (COVID-19)?

Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases

A hyaluronan-based nanosystem enables combined anti-inflammation of mTOR gene silencing and pharmacotherapy

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM)

Cell-mediated delivery of nanoparticles: Taking advantage of circulatory cells to target nanoparticles

Nanoparticle-based drug delivery via RBC-hitchhiking for the inhibition of lung metastases growth

Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude

Initial observations of cell-mediated drug delivery to the deep lung

Human amniotic fluid stem cells labeled with up-conversion nanoparticles for imaging-monitored repairing of acute lung injury

Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis

Neutrophils enable local and non-invasive liposome delivery to inflamed skeletal muscle and ischemic heart

Artificial super neutrophils for inflammation targeting and HClO generation against tumors and infections

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

Engineering cell membrane-based nanotherapeutics to target inflammation

Cellular nanosponges inhibit SARS-CoV-2 infectivity

Cell-membrane-mimicking nanodecoys against infectious diseases

Cell or cell membrane-based drug delivery systems

Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for Induction of antitumor immunity against melanoma

Extracellular vesicles based self-grown gold nanopopcorn for combinatorial chemo-photothermal therapy

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines

Toward nanotechnology-enabled approaches against the COVID-19 pandemic

Advances in therapeutic applications of extracellular vesicles

Intracellularly generated immunological gold nanoparticles for combinatorial photothermal therapy and immunotherapy against tumor

Bone marrow dendritic cells derived microvesicles for combinational immunochemotherapy against tumor

Extracellular vesicles: A new frontier for research in acute respiratory distress syndrome

MSC based therapies-new perspectives for the injured lung

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

Stem cell therapy: A potential approach for treatment of influenza virus and coronavirus-induced acute lung injury

Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome

Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: A review of current literature and potential future treatment options

Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a J o u r n a l P r e -p r o o f and drug delivery: Focusing on the role of surfactant proteins

Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome

Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art

Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy

Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia

Cationic vesicles based on biocompatible diacyl glycerol-arginine surfactants: Physicochemical properties, antimicrobial activity, encapsulation efficiency and drug release

Nanostructured lipid carriers containing a high percentage of a pluronic copolymer increase the biodistribution of novel PDE4 inhibitors for the treatment of traumatic hemorrhage

Controlled delivery of inhaled therapeutic agents

Future of nanomedicines for treating respiratory diseases

Physical principles of nanoparticle cellular endocytosis

Nanocarrier vaccines for SARS-CoV-2

Highly pathogenic coronaviruses: Thrusting vaccine the spotlight

Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses

Contributing factors in the development of acute lung injury in a murine double hit model

A novel swine model of ricin-induced acute respiratory distress syndrome

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and

This research was supported by the National Natural Science Foundation of China J o u r n a l P r e -p r o o f